Currently, several GLS1 inhibitors have been used in clinical trials related to tumor therapy and have shown certain tumor inhibition effect, including lymphoma [26], pancreatic cancer [27] and breast cancer [28]. This evidence concerns the gene GLS and familial pancreatic carcinoma.